BRAF and serous adenocarcinoma: Low-grade serous ovarian carcinoma exhibits a unique genetic profile characterized by KRAS/BRAF mutations compared to high-grade serous carcinoma, thus MEK inhibitors might be appropriate for the treatment of this malignancy (Perrone et al., 2024).